Shire hires global therapeutics head
Shire Pharmaceuticals names Michael Cola as exec VP of global therapeutics area business units. Cola joins Shire on July 1 from Safeguard Scientifics where he was life sciences division president; Cola will report to Shire CEO Matt Emmens. Cola will lead Shire's therapeutic teams, created in 2004, to ensure effective management of existing products and identification of new products for the pipeline...
You may also be interested in...
Join us for an audio catch-up on the latest major developments in the global biopharma industry, as reported by
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.